The "VPS51 subunit of GARP complex" is an integral component of the Golgi-associated retrograde protein (GARP) complex, which is crucial for the tethering and fusion of endosome-derived transport vesicles to the trans-Golgi network (TGN). The GARP complex is a heterotetrameric assembly that includes VPS51, along with VPS52, VPS53, and VPS54, each of which is essential for the complex's function.The role of VPS51, like the other components of the GARP complex, is to recognize and interact with transport vesicles carrying proteins from endosomes back to the Golgi apparatus. This retrograde transport is necessary for the recycling of sorting receptors, the retrieval of escaped Golgi-resident proteins, and the maintenance of Golgi structure and function. VPS51 contributes to the specificity and regulation of vesicle docking, ensuring that cargo is correctly sorted and delivered to its destination within the cell.
Mutations or dysfunctions in the VPS51 subunit or any part of the GARP complex can lead to various cellular anomalies, including trafficking defects that can manifest as disorders. For instance, defects in the GARP complex have been associated with neurological diseases and may contribute to the pathology of certain lysosomal storage disorders.The importance of VPS51 within the GARP complex extends to its potential role in membrane dynamics. By facilitating the fusion of vesicles with the TGN, VPS51 is indirectly involved in the processes that govern the lipid composition and membrane identity of Golgi-derived compartments. The activity of VPS51 and the GARP complex is essential for the preservation of the endolysosomal pathway's balance and for ensuring the fidelity of intracellular protein sorting and trafficking, which are fundamental for cellular homeostasis and function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D is known to inhibit transcription by intercalating into DNA, potentially disrupting the transcription of VPS51. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide functions as a protein synthesis inhibitor in eukaryotic cells, potentially leading to reduced levels of VPS51. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin is a protein synthesis inhibitor that can lead to premature chain termination during translation, potentially reducing VPS51 levels. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil interferes with RNA synthesis and inhibits DNA synthesis, potentially impacting the expression of VPS51 at the transcriptional level. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
Rifampicin inhibits bacterial RNA polymerase, potentially impacting VPS51 expression in bacterial cells. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been suggested to inhibit RNA polymerase II-mediated transcription, potentially impacting the expression of VPS51. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, which can lead to reduced levels of guanosine nucleotides, potentially affecting VPS51 expression. | ||||||